Herpes zoster risk rises across inflammatory bowel disease care
Patients with inflammatory bowel disease face a 1.3- to 2.0-fold higher risk of herpes zoster than the general population, and the excess risk tracks closely with immunosuppressive treatment. In practice, that means the infection risk is not distributed evenly across the IBD population. It concentrates in patients receiving more intensive therapy, especially those exposed to Janus kinase inhibitors, combination regimens, and high-dose corticosteroids.
Younger patients with Crohn’s disease are also vulnerable, which complicates the usual assumption that shingles is mainly a disease of older adults. Immunomodulation weakens the cell-mediated immune response needed to keep latent varicella-zoster virus in check. When that control erodes, reactivation becomes more likely, and so does the downstream burden of acute pain, rash, and postherpetic neuralgia.
A single complication can alter the course of an otherwise stable IBD management plan.
Recombinant zoster vaccine performance holds up in immunosuppressed patients
The recombinant zoster vaccine RZV, marketed as Shingrix, provides strong protection in this setting. Across the evidence summarized in the article, vaccine efficacy ranges from 65% to 90% against herpes zoster, with a meaningful reduction in postherpetic neuralgia as well. Those are clinically important gains, because prevention of shingles does more than avoid a skin eruption; it can spare patients from prolonged neuropathic pain, treatment interruptions, urgent visits, and the knock-on effects that follow an acute infectious episode.
The safety profile is equally important. RZV does not appear to increase IBD flares, even in patients receiving immunosuppressive therapy. That matters because vaccination has sometimes been deferred in immune-mediated disease out of concern that immune stimulation could aggravate intestinal inflammation. The available evidence described here does not support that fear for RZV. Instead, the vaccine fits into IBD care as a preventive intervention that can be delivered without sacrificing disease control.
The biologic logic is straightforward. Because RZV is recombinant and non-live, it avoids the hazards associated with live-attenuated zoster vaccination in immunocompromised hosts while still generating a robust immune response.
Guideline alignment now exceeds real-world uptake
Major professional groups are aligned on the need for vaccination. The American College of Gastroenterology, the European Crohn’s and Colitis Organisation, and the Advisory Committee on Immunisation Practices all support RZV for adults with IBD aged 50 and older, and for those 19 and older who are receiving immunomodulatory therapy. The age threshold is useful, but the more clinically relevant message is broader: the vaccine belongs in routine preventive care for patients whose treatment plan carries a meaningful zoster risk.
The article also emphasizes that benefits appear consistent across age groups, treatment exposures, and ethnic backgrounds. Real-world evidence supports that consistency, which strengthens the case for moving vaccination from a theoretical recommendation to a routine part of IBD management. In a field where treatment decisions already require balancing inflammation control against infectious risk, a preventive intervention with favorable efficacy and safety should not sit on the sidelines.
Implementation still lags behind recommendation.
Access barriers remain sharpest in cost-sensitive regions
The gap between evidence and practice is widest in resource-poor Asian settings, including India, where cost, awareness, and access remain persistent barriers. Those constraints are not merely administrative. They shape whether patients actually receive protection before immunosuppression begins, whether clinicians remember to address vaccination during busy specialty visits, and whether preventive care is treated as part of IBD management or as an optional extra.
A risk-gradient strategy offers a practical response. Instead of trying to vaccinate everyone at the same speed and with the same urgency, this approach prioritizes patients at highest risk for zoster, such as those receiving JAK inhibitors, combination therapy, or high-dose corticosteroids. In a setting where resources are limited, that sequencing can preserve equity while improving yield. It also reflects how risk accumulates in IBD: not all patients carry the same infectious burden, and not all treatment phases are equally dangerous.
The cost question is especially relevant because shingles is not a trivial event. Acute zoster can interrupt work, sleep, nutrition, and medication adherence. Postherpetic neuralgia can outlast the rash by months. Preventing those outcomes is a clinical win, but it also has a direct resource implication for health systems trying to reduce avoidable morbidity.
Routine vaccination needs to move earlier in IBD care pathways
The clearest implication for bedside practice is timing the conversation before immunosuppression escalates risk. Vaccination should be discussed as part of routine IBD care, not as an afterthought once the patient is already deep into a high-risk regimen. For many patients, that means reviewing zoster prevention at the same visit where escalation of therapy is being considered.
For clinicians, the challenge is to normalize vaccination in a population where infection risk changes with every therapeutic step. For patients, the value is concrete: less chance of shingles, less chance of persistent neuralgia, and less chance that a preventable viral reactivation will complicate a disease already managed with chronic medication. The article’s message is direct: RZV is a safe, effective, and cost-efficient way to reduce herpes zoster–associated morbidity in IBD.
What remains unresolved is not whether the vaccine works, but how quickly systems can close the implementation gap across diverse settings, especially where awareness and affordability still determine who gets protected.